Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIP4K2A | P48426 | 8/20 | 0.40 |
| ▸ | PIP4K2B | P78356 | 7/20 | 0.40 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.38 |
| ▸ | TDP2 | O95551 | 1/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.36 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.36 |
| ▸ | CLK1 | P49759 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 3/20 | 0.35 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.35 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.34 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.34 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13049194 | 0.91 | DDB1 (0.32) | PIP4K2APIP4K2BTNIKRIPK2ACVR1 | |
| SCHEMBL2454290 | 0.80 | TNIK (0.39) | PIP4K2APIP4K2BTNIKMAPK10DYRK1B | |
| SCHEMBL1702498 | 0.78 | CRBN (0.47) | PIP4K2APIP4K2BMAPK10DYRK1BCLK1 | |
| SCHEMBL1702806 | 0.76 | MAPK10 (0.41) | PIP4K2APIP4K2BTNIKMAPK10DYRK1B | |
| SCHEMBL1702551 | 0.75 | TNIK (0.38) | PIP4K2APIP4K2BTNIKMAPK10DYRK1B | |
| SCHEMBL2447802 | 0.72 | DYRK1B (0.42) | PIP4K2APIP4K2BTNIKMAPK10DYRK1B | |
| SCHEMBL1530884 | 0.72 | DDB1 (0.39) | — | |
| SCHEMBL1702278 | 0.72 | IKBKB (0.40) | PIP4K2APIP4K2BTDP2MAPK10DYRK1B | |
| SCHEMBL1530139 | 0.71 | TRPV1 (0.42) | PIP4K2APIP4K2BTDP2 | |
| SCHEMBL1530141 | 0.71 | TRPV1 (0.42) | PIP4K2APIP4K2BTDP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2440528-B1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2014-10-08 | — | — | EP | claimed |
| EP-2440528-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2012-04-18 | — | — | EP | claimed |
| WO-2010142656-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-12-16 | — | — | WO | claimed |
| US-20100311760-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | DE VICENTE FIDALGO JAVIER | 2010-12-09 | — | — | US | claimed |
| EP-2440528-B1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2014-10-08 | — | — | EP | disclosed |
| EP-2440528-B1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2014-10-08 | — | — | EP | disclosed |
| US-8487103-B2 | Quinoline inhibitors of hepatitis C virus polymerase | ROCHE PALO ALTO LLC (US) | 2013-07-16 | — | — | US | disclosed |
| US-8487103-B2 | Quinoline inhibitors of hepatitis C virus polymerase | ROCHE PALO ALTO LLC (US) | 2013-07-16 | — | — | US | disclosed |
| US-20110300103-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ROCHE PALO ALTO LLC (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110300103-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ROCHE PALO ALTO LLC (US) | 2011-12-08 | — | — | US | disclosed |
| US-8026253-B2 | Quinoline inhibitors of HCV polymerase | ROCHE PALO ALTO LLC (US) | 2011-09-27 | — | — | US | disclosed |
| US-8026253-B2 | Quinoline inhibitors of HCV polymerase | ROCHE PALO ALTO LLC (US) | 2011-09-27 | — | — | US | disclosed |
| US-20100311760-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | DE VICENTE FIDALGO JAVIER | 2010-12-09 | — | — | US | disclosed |
| US-20100311760-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | DE VICENTE FIDALGO JAVIER | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311760-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | EIF2AK2, XDH, GTF3C4 | PIP4K2A 2111/4885PIP4K2B 1750/4885TNIK 3946/4885 |
| US-20110300103-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, IRF3 | PIP4K2A 2698/4885PIP4K2B 2468/4885TNIK 3560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.